Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Marika Sherman"'
Autor:
Ranjit Nair, Gaëlle Drillet, Faustine Lhomme, Anthony Le Bras, Laure Michel, John Rossi, Marika Sherman, Allen Xue, Anne Kerber, Nutchawan Jittapiromsak, Linda Chi, Sudhakar Tummala, Sattva S. Neelapu, Roch Houot
Publikováno v:
Haematologica, Vol 106, Iss 5 (2020)
Externí odkaz:
https://doaj.org/article/32393e9fbf384c0c998137ec79cf8509
Autor:
Sandra L Ross, Marika Sherman, Patricia L McElroy, Julie A Lofgren, Gordon Moody, Patrick A Baeuerle, Angela Coxon, Tara Arvedson
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183390 (2017)
For targets that are homogenously expressed, such as CD19 on cells of the B lymphocyte lineage, immunotherapies can be highly effective. Targeting CD19 with blinatumomab, a CD19/CD3 bispecific antibody construct (BiTE®), or with chimeric antigen rec
Externí odkaz:
https://doaj.org/article/da6de4d7994f403384257b718f9d5ae2
Autor:
Jeffrey Ward, Armin Ghobadi, John Liao, Adam Schoenfeld, Scott Tykodi, Yizhou Jiang, John Le Gall, Ruben Alvarez-Rodriguez, Marika Sherman, Tiffany Singson, Jeffrey McLeroy
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Irit Avivi, Tom van Meerten, Jenny J. Kim, Marika Sherman, John M. Rossi, Roch Houot, Monique C. Minnema, Jinghui Dong, Martin Wermke, John Kuruvilla, Yan Zheng, Max S. Topp, Kevin W. Song, Saran Vardhanabhuti, Ulrich Dührsen, Adrian Bot, Marie José Kersten, Vicki Plaks, Anne Kerber, Catherine Thieblemont, Pieternella J. Lugtenburg, Krimo Bouabdallah
Publikováno v:
British journal of haematology, 195(3), 388-398. Wiley-Blackwell
The Lancet. Oncology
British Journal of Haematology, 195(3), 388-398. Wiley
British Journal of Haematology, 195(3), 388-398. Wiley-Blackwell Publishing Ltd
The Lancet. Oncology
British Journal of Haematology, 195(3), 388-398. Wiley
British Journal of Haematology, 195(3), 388-398. Wiley-Blackwell Publishing Ltd
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory large B-cell lymphoma (R/R LBCL). To reduce axi-cel–related toxicity, several exploratory safety managem
Autor:
Patrick M. Reagan, David B. Miklos, Jeffrey S. Wiezorek, Adrian Bot, Frederick L. Locke, John M. Rossi, Marc Better, Olalekan O. Oluwole, Lazaros J. Lekakis, Caron A. Jacobson, Yi Lin, William Y. Go, Armin Ghobadi, Allen Xue, Marika Sherman, Sattva S. Neelapu
Publikováno v:
Blood Adv
ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously
Autor:
Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph Rosenblatt, Marika Sherman, Jinghui Dong, Alessandro Giovanetti, Yin Yang, Christine Lui, Zahid Bashir, A. Scott Jung, Caron A. Jacobson
Publikováno v:
Transplantation and Cellular Therapy. 28:S64-S65
Autor:
Ibrahim Yakoub-Agha, David G. Maloney, Emmanuel Bachy, A Scott Jung, Pashna N. Munshi, Carla Casulo, Ran Reshef, Olalekan O. Oluwole, Narendranath Epperla, Christine Lui, Joseph D. Rosenblatt, Matthew L. Ulrickson, Alison R. Sehgal, Sven de Vos, Yin Yang, Marika Sherman, Lori A. Leslie, Caron A. Jacobson, Rashmi Khanal, Alessandro Giovanetti, Zahid Bashir, Julio C. Chavez, Jinghui Dong, Sattva S. Neelapu
Publikováno v:
Blood. 138:93-93
Background: Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of R/R large B-cell lymphoma and follicular lymphoma (FL), both after ≥2 lines of systemic therapy. ZUMA-5 is a Phase 2, multic
Autor:
David B. Miklos, John M. Rossi, Gabrielle Palluconi, Michael D. Jain, N. Nora Bennani, John M. Timmerman, Ran Reshef, Jenny J. Kim, Lianqing Zheng, Marika Sherman, Jennifer Sun, Caron A. Jacobson
Publikováno v:
Blood. 134:4084-4084
Background: Relapsed/refractory (R/R) large B cell lymphoma (LBCL) is associated with poor outcomes to standard salvage therapy (Crump M, et al. Blood. 2017). In SCHOLAR-1, a large multicenter, patient-level, retrospective study, patients with R/R di
Autor:
Sandra L. Ross, not provided Marika Sherman, not provided Patricia L. McElroy, not provided Julie A. Lofgren, not provided Gordon Moody, not provided Patrick A. Baeuerle, not provided Angela Coxon, not provided Tara Arvedson
This protocol describes methods for a mouse xenograft study designed to measure in vivo BiTE®efficacy against antigen-expressing human tumor cells. In a modified version, the protocol is used to measure BiTE®-mediated bystander killing. Mixtures of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d904c7c2462e37ffb274ab8d72215e75
https://doi.org/10.17504/protocols.io.h5eb83e
https://doi.org/10.17504/protocols.io.h5eb83e
Autor:
Sandra L. Ross, not provided Marika Sherman, not provided Patricia L. McElroy, not provided Julie A. Lofgren, not provided Gordon Moody, not provided Patrick A. Baeuerle, not provided Angela Coxon, not provided Tara Arvedson
This protocol describes two methods for assessing whether soluble factors alone or a combination of soluble factors and T cells are responsible for bystander killing: (1) Supernatant transfer assays and (2)Transwell® assays.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a88b637ba298838afa5509997ea1e2b4
https://doi.org/10.17504/protocols.io.h3vb8n6
https://doi.org/10.17504/protocols.io.h3vb8n6